Cargando…
Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy
Disruption of microtubule function is the antitumor mechanism of several classes of drugs used to treat cancer today. However, the significant beneficial effect on tumor outcomes is frequently counterbalanced by neurotoxic complications. Despite an abundance of scientific data, our under-standing of...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Libertas Academica
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820064/ https://www.ncbi.nlm.nih.gov/pubmed/27081324 http://dx.doi.org/10.4137/CMO.S32810 |
_version_ | 1782425329787207680 |
---|---|
author | Higa, Gerald M. Sypult, Corbin |
author_facet | Higa, Gerald M. Sypult, Corbin |
author_sort | Higa, Gerald M. |
collection | PubMed |
description | Disruption of microtubule function is the antitumor mechanism of several classes of drugs used to treat cancer today. However, the significant beneficial effect on tumor outcomes is frequently counterbalanced by neurotoxic complications. Despite an abundance of scientific data, our under-standing of the biological mechanisms underlying this toxic reaction remains unclear, further hindering attempts to identify and develop effective preventive strategies. The primary goals of this review are to: (1) provide insight regarding the biology of the microtubule, (2) analyze the molecular and biochemical pathways that may be involved in the development of neurotoxicity, and (3) propose a unifying concept linking drug-induced neuropathy, microtubule dysfunction, and vitamin D. |
format | Online Article Text |
id | pubmed-4820064 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | Libertas Academica |
record_format | MEDLINE/PubMed |
spelling | pubmed-48200642016-04-14 Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy Higa, Gerald M. Sypult, Corbin Clin Med Insights Oncol Review Disruption of microtubule function is the antitumor mechanism of several classes of drugs used to treat cancer today. However, the significant beneficial effect on tumor outcomes is frequently counterbalanced by neurotoxic complications. Despite an abundance of scientific data, our under-standing of the biological mechanisms underlying this toxic reaction remains unclear, further hindering attempts to identify and develop effective preventive strategies. The primary goals of this review are to: (1) provide insight regarding the biology of the microtubule, (2) analyze the molecular and biochemical pathways that may be involved in the development of neurotoxicity, and (3) propose a unifying concept linking drug-induced neuropathy, microtubule dysfunction, and vitamin D. Libertas Academica 2016-04-03 /pmc/articles/PMC4820064/ /pubmed/27081324 http://dx.doi.org/10.4137/CMO.S32810 Text en © 2016 the author(s), publisher and licensee Libertas Academica Ltd. This is an open access article published under the Creative Commons CC-BY-NC 3.0 license. |
spellingShingle | Review Higa, Gerald M. Sypult, Corbin Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy |
title | Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy |
title_full | Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy |
title_fullStr | Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy |
title_full_unstemmed | Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy |
title_short | Molecular Biology and Clinical Mitigation of Cancer Treatment-Induced Neuropathy |
title_sort | molecular biology and clinical mitigation of cancer treatment-induced neuropathy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4820064/ https://www.ncbi.nlm.nih.gov/pubmed/27081324 http://dx.doi.org/10.4137/CMO.S32810 |
work_keys_str_mv | AT higageraldm molecularbiologyandclinicalmitigationofcancertreatmentinducedneuropathy AT sypultcorbin molecularbiologyandclinicalmitigationofcancertreatmentinducedneuropathy |